Haemostatic management in high-risk cardiac surgery: A role of recombinant factor VIIa (novoseven RT)

European Journal of Cardio-thoracic Surgery

Volumn 42, Issue 3, 2012, Pages 606-607

  Petricevic, Mate ^a   Biocina, Bojan ^a   Konosic, Sanja ^a   Burcar, Ivan ^a  

^a KBC Zagreb   (Croatia)

Author keywords

Factor VII; Haemorrhage; Re exploration; Recombinant factor VIIa

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; RECOMBINANT BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 7A; COAGULATING AGENT;

BLEEDING; BLOOD TRANSFUSION; CORONARY ARTERY BYPASS SURGERY; HUMAN; LETTER; POINT OF CARE TESTING; PREVALENCE; PRIORITY JOURNAL; REOPERATION; THROMBOCYTE FUNCTION; THROMBOELASTOGRAPHY; FEMALE; HEART SURGERY; MALE; NOTE; POSTOPERATIVE HEMORRHAGE;

CARDIAC SURGICAL PROCEDURES; COAGULANTS; FACTOR VIIA; FEMALE; HUMANS; MALE; POSTOPERATIVE HEMORRHAGE;

EID: 84872686302     PISSN: 10107940     EISSN: 1873734X     Source Type: Journal    
DOI: 10.1093/ejcts/ezs166     Document Type: Letter

References (3)

1. Chapman AJ, Blount AL, Davis AT, Hooker RL. Recombinant factor VIIa (NovoSeven RT) use in high risk cardiac surgery. Eur J Cardiothorac Surg 2011;40:1314-8; discussion 1318-9.
2. Hacquard M, Durand M, Lecompte T, Boini S, Briancon S, Carteaux JP. Off-label use of recombinant activated factor VII in intractable haemorrhage after cardiovascular surgery: an observational study of practices in 23 French cardiac centres (2005-7). Eur J Cardiothorac Surg 2011; 40:1320-7.
3. Spiess BD, Gillies BS, Chandler W, Verrier E. Changes in transfusion therapy and reexploration rate after institution of a blood management program in cardiac surgical patients. J Cardiothorac Vasc Anesth 1995;9: 168-73.